A sea of paperwork or business as usual? Steven Gray looks ahead to the soon-to-be finalised 2008 ABPI Code of Practice and how it will affect everyday practice in the UK industry(more)
Delays push SkyePharma back into red Drug delivery specialist SkyePharma losses grew in the first half of 2003 to £18.6m due primarily to delays to several milestone payments...(more)
AstraZeneca exits NicOx collaboration French biotech company NicOx has seen its shares lose nearly 25% of their value after AstraZeneca abandoned a joint venture to development the new CINOD class of painkillers...(more)
Novartis' Cox-II challenger suffers set back Prexige, the new challenger to the established Cox-II drugs from Novartis has been dealt a serious blow after the FDA issued it with a non-approvable letter...(more)
Push for greater data transparency, NICE told A special World Health Organisation team has praised the groundbreaking work of NICE but has called for its dealing with industry to be more transparent...(more)
First generic challenger to Paxil hits US market Apotex has launched the first generic version of GlaxoSmithKline blockbuster antidepressant Paxil (paroxetine) in the US, several months earlier than expected...(more)
AstraZeneca claims Symbicort superior to Seretide AstraZeneca says new data shows its asthma treatment Symbicort outperformed rival treatment GlaxoSmithKline Seretide, in their first ever head-to-head clinical trial...(more)
UK invests in cancer research programme The UK Government has promised faster access to new and experimental treatments for cancer patients through a new Oxford-based research centre...(more)
New data boosts AstraZeneca's Atacand New trial data on AstraZeneca's blood pressure treatment Atacand could give the drug a lead over rivals in the same class and a significant boost to its sales...(more)
European HRT safety probe launched The European Union medicines regulator is to investigate the safety of hormone replacement therapy products following a new study was published showing an increased risk of breast cancer...(more)
Call for free price-setting across Europe Pharmaceutical companies should be allowed to set their own prices in all the European Union countries in order to bring a single market one step closer, the European Commission has said...(more)
GSK's 'sleeping giant' awakens in US GlaxoSmithKline has gained FDA approval for an extended release version of its antidepressant Wellbutrin, giving the company vital new patent protection...(more)
Exanta shows positive results for AstraZeneca AstraZeneca has received a boost with the release of two positive studies for its new blood-thinning drug Exanta despite questions remaining over its effects on patient's livers...(more)
